CPHI Japan 2025
Join us to learn how we can streamline and optimize your API sourcing
Meet us at Suite 5N-12
April 9 - 11, 2025
Tokyo Big Sight, East Hall 4, 5 & 6, Tokyo, JapanOur Team at CPHI Japan 2025
Nirav Shah
Vice President, and Head, API - North Asia
Masahiro Wakabayashi
Director, API Sales & Marketing, Japan
Sriram Karthikeya Chavali
Associate Director, Business Development, Japan
Dr. Akihito Kitajima
Head, API Regulatory Affairs, Japan
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
-
250+ APIs
-
8 Manufacturing sites
-
1950 drug master files across global markets.
-
Over 325 ANDAs
-
More than 1000 patents field, and more than 70 own patents granted
-
Experience with complex APIs and formulations supporting early market entries.
-
Preferred pharma API supplier for pharma companies in more than 80 countries.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
What we achieved in the past year:
Our Achievement (awards)
25/04/2024
USP recognized Dr. Reddy’s with a crystal award for significant contribution towards “New and modernized monograph submissions”
05/04/2024
Dr. Reddys Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya
05/12/2023
Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our Plants
About CPHI Japan 2025
CPHI Japan 2025 is a leading event in the pharmaceutical industry, set to take place from April 9 to 11, 2025, at Tokyo Big Sight in Tokyo, Japan. Bringing together over 26,000 industry professionals and 730+ exhibitors from 60 countries, the event serves as a key platform for networking, collaboration, and knowledge-sharing. With a strong focus on innovation and business growth, CPHI Japan covers the entire pharmaceutical supply chain, offering insights into the latest trends, regulatory updates, and technological advancements shaping the industry.
Networking is at the heart of CPHI events, offering professionals a chance to build meaningful partnerships and strengthen existing collaborations. Dedicated networking lounges, informal meetups, and digital matchmaking tools help attendees connect with potential business partners, service providers, and key decision-makers. The event creates opportunities to explore new markets, establish supply chain relationships, and stay informed about the latest innovations driving the pharmaceutical sector forward. Join us to discover our innovative solutions, and learn how we can contribute to the advancement of the pharmaceutical sector together
免责声明
本目錄中的任何信息（包括對任何產品或服務的任何引用）均不構成銷售要約，或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是，只要存在此類監管豁免，就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估，並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途，但可用於第 107A 節。